The CDC’s new recommendations to routinely test most Americans for HIV is expected to be profitable for Abbott Laboratories and OraSure Technologies, the Chicago Tribune reports, because Abbott distributes the rapid HIV tests that OraSure manufactures. Even before the CDC’s announcement last week, anticipated for months, Abbott had purchased 120% more tests from OraSure than in the same period last year.